Programs and initiatives


The following programs and initiatives are built to realize the Institute’s ambitious plans and to ensure OICR’s research will be translated to results for patients. To better understand how these programs and initiatives fit together, read about our strategy here.

Jump to: Adaptive Oncology | Clinical Translation | Therapeutic Innovation

Adaptive Oncology

Develop knowledge and approaches to monitor cancer over its lifecycle in order to enable precise and proactive clinical management.

Computational Biology

The Computational Biology Program is the scientific engine of research and analytics at OICR.

More details about Computational Biology →

Diagnostic Development

The Diagnostic Development Program’s mission is to initiate, disseminate and nurture expertise in the development of diagnostic assays and support the rapid implementation of precision medicine.

More details about Diagnostic Development →

Genome Informatics

The Genome Informatics Program develops new software, databases and other necessary components to store, organize and compute over the large and complex datasets being generated by OICR’s cancer research programs

More details about Genome Informatics →


The Genomics Program provides large-scale, next generation sequencing cancer genomics capabilities to researchers in Ontario and beyond.

More details about Genomics →

Global Alliance for Genomics and Health

The Global Alliance for Genomics and Health (GA4GH) was formed to help accelerate the potential of genomic medicine to advance human health.

More details about Global Alliance →


The goal of the ICGC is to generate comprehensive catalogues of genomic abnormalities in tumours from 50 different cancer types.

More details about the ICGC →


The Imaging Program accelerates translation of research findings and developments of new imaging techniques and probes of cancer into clinical practice.

More details about Imaging →


Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) is a new OICR-supported initiative that provides next generation sequencing-based molecular profiling at multiple Ontario cancer centres.

More details about Octane →

Ontario Health Study

The Ontario Health Study is a landmark study with over 225,000 participants that will help researchers better understand the environmental, lifestyle, and genetic factors that cause cancer and other chronic diseases.

More details about the Ontario Health Study →

Ontario Molecular Pathology Research Network

The Ontario Molecular Pathology Research Network is a province-wide network of pathologists collaborating to carry out high-quality cancer research with a clear potential for clinical impact.

More details about OMPRN →

Ontario Tumour Bank

The Ontario Tumour Bank is a province-wide biorepository and data bank focused on collection of tumour-related human biospecimens.

More details about OTB →

Translational Genomics Laboratory

The Transformative Genomics Laboratory was built to fulfill an unmet need and further the use of genomics technologies in the clinical oncology space.

More details about TGL →


Clinical Translation

Advance cancer studies through early clinical validation, partnering with industry and the health system for downstream development and patient impact.

Canadian Cancer Clinical Trials Network

The Canadian Cancer Clinical Trials Network is a pan-Canadian initiative to improve the efficiency and quality of clinical trials in Canada.

More details about CCCTN →

Health Services Research Network

The Health Services Research Network provides the knowledge needed to optimize the delivery of cancer services today and to ensure appropriate dissemination of health service innovations and well-evaluated technologies

More details about Health Services Research →

Ontario Cancer Research Ethics Board

The Ontario Cancer Research Ethics Board is an expert central oncology REB serving almost every hospital in Ontario that conducts cancer clinical trials.

More details about OCREB →

Translational Research Initiatives (TRI)

Large-scale, multi-institutional collaborations between laboratory and clinician-scientists to advance Ontario research to improve cancer patient outcomes.

Acute Leukemia TRI

The goal of the Acute Leukemia TRI is to improve outcomes for patients by developing new biomarkers that can be used to better predict how patients will respond to therapy.

More details about the Acute Leukemia TRI→

Brain cancer TRI

The goal of the Brain Cancer TRI is to investigate the cellular and genetic differences (heterogeneity) of Medulloblastoma (MB) and Glioblastoma Multiforme (GBM) in children and adults.

More details about the Brain Cancer TRI →

Ovarian Cancer TRI

The goal of the Ovarian Cancer TRI is to better understand how ovarian cancer develops, what causes resistance to current therapy and how ovarian cancer can be better targeted with new therapies.

More details about the Ovarian Cancer TRI→

Pancreatic Cancer TRI (PanCuRx)

PanCuRx seeks solutions to the high fatality rate of pancreatic cancer by generating new knowledge about genetic and biologic subsets of disease, mechanisms of tumorigenesis and tailored treatment options.

More details about the  Pancreatic cancer TRI →

Immuno-oncology TRI

The goal of the Immuno-oncology TRI is to develop and clinically test an OICR-supported oncolytic virus treatment in combination with two cutting-edge immunotherapy strategies in order to improve outcomes for cancer patients, specifically for those with advanced metastatic cancers.

More details about the Immuno-oncology TRI →

Therapeutic Innovation

Validate novel cancer drug targets and advance selective therapeutic candidates through pre-clinical development

Cancer Therapeutics Innovation Pipeline

CTIP supports the local translation of Ontario discoveries into therapies with the potential for improving the lives of cancer patients

More details about CTIP →

Drug Discovery

The Drug Discovery Program helps efficiently translate discoveries made in Ontario’s labs into novel oncology therapies.

More details about Drug Discovery →